- Home
- NNVC vs BCAB Comparison
NNVC vs BCAB Comparison
Compare NNVC & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNVC
- BCAB
- Stock Information
- Founded
- NNVC 2005
- BCAB 2007
- Country
- NNVC United States
- BCAB United States
- Employees
- NNVC N/A
- BCAB N/A
- Industry
- NNVC Biotechnology: Pharmaceutical Preparations
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- NNVC Health Care
- BCAB Health Care
- Exchange
- NNVC Nasdaq
- BCAB Nasdaq
- Market Cap
- NNVC 24.1M
- BCAB 21.6M
- IPO Year
- NNVC N/A
- BCAB 2020
- Fundamental
- Price
- NNVC $1.42
- BCAB $0.45
- Analyst Decision
- NNVC
- BCAB Hold
- Analyst Count
- NNVC 0
- BCAB 3
- Target Price
- NNVC N/A
- BCAB $1.00
- AVG Volume (30 Days)
- NNVC 123.5K
- BCAB 594.1K
- Earning Date
- NNVC 09-26-2025
- BCAB 08-07-2025
- Dividend Yield
- NNVC N/A
- BCAB N/A
- EPS Growth
- NNVC N/A
- BCAB N/A
- EPS
- NNVC N/A
- BCAB N/A
- Revenue
- NNVC N/A
- BCAB $11,000,000.00
- Revenue This Year
- NNVC N/A
- BCAB N/A
- Revenue Next Year
- NNVC N/A
- BCAB N/A
- P/E Ratio
- NNVC N/A
- BCAB N/A
- Revenue Growth
- NNVC N/A
- BCAB N/A
- 52 Week Low
- NNVC $0.94
- BCAB $0.24
- 52 Week High
- NNVC $1.92
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- NNVC 42.16
- BCAB 61.95
- Support Level
- NNVC $1.37
- BCAB $0.41
- Resistance Level
- NNVC $1.54
- BCAB $0.46
- Average True Range (ATR)
- NNVC 0.07
- BCAB 0.03
- MACD
- NNVC -0.01
- BCAB 0.01
- Stochastic Oscillator
- NNVC 32.91
- BCAB 81.89
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.